MindMed Publishes Report by Leading FDA Experts Validating MindMed's MM-120 Drug Development Strategy
Independent Third-Party Firm, Led by Former Senior FDA Officials, Calls Phase 2b Trial “Well-designed” and “Essential” Report Further Demonstrates that FCM’s Proposal... | May 25, 2023
Source: marketscreener.com